Skip to main content
Caplight Logo









Enodia Therapeutics

Enodia Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.enodiatx.com/

Last Round

Seed

Jan 8, 2026

Total Funding Raised

$25M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Enodia Therapeutics is a biotechnology company that develops small-molecule therapies that enable the degradation of disease-driving proteins at the point of synthesis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoverysmall molecule inhibitorsSec61 translocononcology therapeuticsprotein homeostasispreclinical drug developmentbiotechrational drug designai drug discoverytherapeutic pipelinedrug discovery platformin silico drug designbiopharmaprotein secretion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enodia Therapeutics Comparables

Compare Enodia Therapeutics with similar companies based on industry and business-model similarity.

Enodia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gate Bioscience
79%
Initial Therapeutics
73%
Sibylla Biotech
71%

Enodia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 8, 2026

Key People

Founding team and executive leadership

Yves Ribeill

Chief Executive Officer

Executive Team

Enodia Therapeutics Investors

Notable investors and investment history

Enodia Therapeutics investors
InvestorRounds
InvestsudSeed
Elaia PartnersSeed
Wallonie EntreprendreSeed
Pfizer VenturesSeed
Mission BioCapitalSeed
Institut PasteurSeed
SambrinvestSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 18, 2026

    Grew 50% QoQ, from 8 to 12 employees.

  • May 18, 2026

    Grew 120% QoQ, from 5 to 11 employees.

Enodia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enodia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enodia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range12
Year Founded2025
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?